Share this post on:



FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 05/2022”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

As of the end of  May 2022 we identify the following current VC trends in Europe:

  • In 2022, overall Life Sciences funding has reached EUR 4,205m so far
  • Top 5 Deals exceed EUR 90m each, largest transaction amounted to EUR 500m in Doctolib (France)
  • Bpifrance dominates the Top 5 Investors (by deal volume), followed by Eurazeo (France) and General Atlantic (United States)
  • The Biotech sector received 42% of the total investment volume, (-1% point compared to the previous month)
  • Oncology still dominates as the top indication of the Biotechnology sector

To access the full report, please click here.

By Dr. Mathias Schott, Sebastian Sommer and Johannes Link




Source link

Share this post on:

Leave a Comment

Your email address will not be published.